Research. Advocacy. Support.
We advance ovarian cancer research while supporting women and their families.
Your Gift x 2
Give to OCRFA by December 31, and your donation will be matched dollar for dollar up to $250,000 by a generous board member.
Know Your Risks
About 20 to 25 percent of women diagnosed with ovarian cancer have a hereditary tendency to develop the disease.
Many factors can increase or decrease a woman's risk of developing ovarian cancer.
- Family history of breast, ovarian or colon cancer
- Genetic mutations like BRCA
- Increased age
- Use of oral contraceptives
Know the Symptoms
- Difficulty Eating
- Pelvic / Abdominal Pain
- Urinary Frequency
If these symptoms occur for more than 2 weeks and these symptoms are new or unusual for you, see a gynecologist and ask about ovarian cancer. Research shows that seeing a gynecologic oncologist for surgery and treatment significantly improves outcomes.
Share Your #OvarianStory
Every ovarian cancer survivor's voice has power. Hear Emily's story and use #OvarianStory to share your own.
The Relationship Between Cytotoxic CD8 Tumor-Infiltrating Lymphocytes and Overall Survival in High Grade Serous Ovarian Cancer
(December 11, 2017) A study by the Ovarian Tumor Tissue Analysis Consortium, published in JAMA Oncology, looked at the association between cytotoxic CD8+ tumor-infiltrating lymphocytes (TILs) and overall survival with certain types of ovarian cancer. After an immunohistochemical analysis of 5,577 patients, researchers saw a strong correlation between high levels of CD8+ TILs and longer… More
(December 8, 2017) The results of the CONCORD-2 study, recently published in Cancer, show a large difference in ovarian cancer survival between black women and white women, and also between stages at diagnosis. The data collected from the study, the largest of its kind, looked at 172,849 cases of ovarian cancer, over the course of… More
(December 4, 2017) The results of a phase II trial, which focused on stages IIB to IVA epithelial ovarian cancer, were recently published in the Annals of Oncology. The primary purpose of the six year, two stage, multicenter trial was to look at the nine month progressive disease rate when using intraperitoneal (IP) chemotherapy after… More
OCRFA’s indoor cycling event comes to Philadelphia on January 13, 2018. Ride for a cure for ov...January 13, 2018 @ 12:30 pm - 2:30 pm EST
Join us for an unforgettable night to defeat ovarian cancer. 50+ chefs and mixologists 400+ attendee...March 7, 2018 @ 6:00 pm - 8:30 pm EST